Benefit of Transradial Approach in Chronic Kidney Disease Population Undergoing Cardiac Catheterization
Benefit of Transradial Approach in Chronic Kidney Disease Population Undergoing Cardiac Catheterization
The investigators will conduct a randomized controlled trial that aims to compare the
 incidence of contrast-induced nephropathy between transradial- and transfemoral-access
 cardiac catheterization.
Cardiac catheterization is a medical procedure used to diagnose and treat heart conditions.
 Approaching the heart can be done by different access sites: via the femoral artery
 (transfemoral) or the radial artery (transradial). Transfemoral access (TFA) is the primary
 mode of arterial access. Several clinical trials have demonstrated the benefit of transradial
 over transfemoral approach. The primary advantage of transradial approach is a significant
 reduction of access-site complications. Chronic Kidney Disease (CKD) is a serious condition
 associated with premature mortality, decreased quality of life, and increased health-care
 expenditures. ). It is commonly found in patients with diabetes, hypertension,
 hyperlipidemia, coronary artery disease, or combinations of these risk factors. Coronary
 artery disease and CKD are often comorbid conditions seen in the cath lab. Cardiac
 catheterization is a mainstay of diagnosis and treatment for coronary artery disease and 58%
 of deaths in CKD are related to cardiovascular deaths. Patients with CKD and who undergo a
 cardiac catheterization are at risk for contrast-induced nephropathy (CIN) due to the dye
 used during the procedure.

 The investigators will conduct a randomized controlled trial that aims to compare the
 incidence of CIN between transradial and transfemoral cardiac catheterization.
Inclusion Criteria:

 1. Patients scheduled to undergo non-emergent cardiac catheterization at University
 Medical Center Hospital, Lubbock, TX from January 2016 to January 2018. Emergent
 cardiac catheterizations will be defined as a catheterization scheduled < 24 hours
 from a cardiac event.

 2. Patients willing to be randomized to TFA or TRA procedure.

 3. Patients signed and dated the informed consent agreeing to participate in the study.

 4. Patients with chronic kidney disease, defined as eGFR = 15-59mL/min defined by the
 MDRD formula. (eGFR is a standard of care measurement for all patients undergoing
 coronary intervention.).

 5. Patients ages 18-88 years old.

 Exclusion Criteria:

 1. Patients who have previously undergone a coronary artery bypass graft procedure.

 2. Patients with prior catheterization within the last 5 years.

 3. Women who are pregnant or expect to become pregnant. Pregnancy tests for women of
 childbearing potential (WOCHP) will be performed as standard of care.

 4. Patients with a history of cardiogenic shock.

 5. Children (under the age of 18).

 6. Medical, geographical, or social factors making study participation impractical, i.e.
 documented noncompliance, unable to return for follow-ups and lab draws, etc.

 7. A positive Allen's Test on the right radial artery.

 8. Any condition preventing TRA or TFA access.

 9. Contrast used within the previous 3 weeks.

 10. Allergy to contrast dye.

 11. Inability to successfully access the artery randomized to use.